



Published in final edited form as:

J Immunol. 2009 April 1; 182(7): 3969–3973. doi:10.4049/jimmunol.0803514.

Cutting Edge: Acute Lung Allograft Rejection Is Independent of Secondary Lymphoid Organs¹

Andrew E. Gelman^{*,†}, Wenjun Li^{*}, Steven B. Richardson^{*}, Bernd H. Zinselmeyer[†], Jiaming Lai^{*}, Miki Okazaki^{*}, Christopher G. Kornfeld^{*}, Friederike H. Kreisel[†], Seichiro Sugimoto^{*}, Jeremy R. Tietjens^{*}, John Dempster[‡], G. Alexander Patterson^{*}, Alexander S. Krupnick^{*}, Mark J. Miller[†], and Daniel Kreisel^{2,*,†}

^{*}Department of Surgery, Washington University, St. Louis, MO 63110

[†]Department of Pathology and Immunology, Washington University, St. Louis, MO 63110

[‡]Department of Physiology and Pharmacology, University of Strathclyde, Glasgow, Scotland, United Kingdom

Abstract

It is the prevailing view that adaptive immune responses are initiated in secondary lymphoid organs. Studies using alymphoplastic mice have shown that secondary lymphoid organs are essential to initiate allograft rejection of skin, heart, and small bowel. The high immunogenicity of lungs is well recognized and allograft rejection remains a major contributing factor to poor outcomes after lung transplantation. We show in this study that alloreactive T cells are initially primed within lung allografts and not in secondary lymphoid organs following transplantation. In contrast to other organs, lungs are acutely rejected in the absence of secondary lymphoid organs. Two-photon microscopy revealed that recipient T cells cluster predominantly around lung-resident, donor-derived CD11c⁺ cells early after engraftment. These findings demonstrate for the first time that alloimmune responses following lung transplantation are initiated in the graft itself and therefore identify a novel, potentially clinically relevant mechanism of lung allograft rejection.

It is generally accepted that immune responses to foreign Ags are initiated in secondary lymphoid organs. However, the location where T cells initially encounter alloantigen after transplantation has been the focus of numerous investigations and is still unresolved. Medawar described the first stage of allograft rejection as “peripheral sensitization,” during which recipient lymphocytes interact with Ags in the graft itself (1). However, subsequent studies have challenged this concept. To this end, rejection of skin grafts can be prevented when afferent lymphatic drainage is disrupted, indicating the importance of trafficking to secondary lymphoid organs (2). These observations were extended by demonstrating that alymphoplastic (*aly/aly*) mice that lack peripheral lymph nodes and Peyer’s patches do not reject allogeneic skin grafts (3). Splenectomized *aly/aly* mice are unable to reject hearts, and cardiac allograft survival is dramatically prolonged after transplantation into splenectomized lymphotoxin- α -deficient or lymphotoxin- β receptor-deficient hosts (3, 4). Small bowel is

¹D.K. was supported by National Heart, Lung, and Blood Institute Grant 1K08HL083983 and by the Thoracic Surgery Foundation for Research and Education.

Copyright © 2009 by The American Association of Immunologists, Inc.

²Address correspondence and reprint requests to Dr. Daniel Kreisel, Assistant Professor of Surgery, Pathology and Immunology, Campus Box 8234, 660 South Euclid Avenue, Washington University, St. Louis, MO 63110-1013. kreiseld@wudosis.wustl.edu.

Disclosures

The authors have no financial conflict of interest.

not rejected when both donor and recipient lack secondary lymphoid organs, and graft vs host disease following bone marrow transplantation can be prevented by blocking the access of T cells to secondary lymphoid organs (5, 6). Thus, these studies suggest that encountering alloantigen through contact with APCs in secondary lymphoid organs is a requirement for T cell activation following transplantation.

Lungs are particularly immunogenic, with clinical data demonstrating the highest rejection rates among all solid organ grafts. Similar to other organs, the majority of studies examining pulmonary immune responses have concluded that the activation of T cells occurs exclusively in draining lymph nodes and that the lung is not a suitable environment for the activation of naive T cells (7–9). However, there also exist reports that pulmonary APCs have the capacity to activate CD4⁺ T cells locally within the lung and that adaptive immune responses to respiratory viruses can be generated in mice that lack secondary lymphoid organs (10, 11). We asked whether the priming of alloimmune responses to lungs and their rejection are dependent on secondary lymphoid organs.

Materials and Methods

Mice

C57BL/6 (B6), C3H/HeJ (C3H), CBA/Ca (CBA), and B6 CD45.1⁺ mice were purchased from The Jackson Laboratory. B6 CD11c⁺-enhanced yellow fluorescent protein (EYFP)³-positive mice were a gift from M. Nussenzweig (The Rockefeller University, New York, NY). Male B6 *aly/aly* mice (CLEA Japan) were bred with female C3H mice. Their B6C3F1 *aly/+* offspring were intercrossed to produce B6C3F2 mice, which were then screened for expression of the *aly* mutation of NF- κ B-inducing kinase and genotyped for H-2K^k and K^b (5). B6C3F2 *aly/aly* mice expressing at least one H-2K^k allele (B6C3F2 K^{k/b} *aly/aly*) were used as donors.

Transplantation

Lungs and hearts were transplanted in 8- to 10-wk old mice (12). Graft histology was assessed in a blinded fashion.

Adoptive transfers

CD90⁺ T cells were purified from spleens of B6, B6 CD45.1⁺, or CBA mice with magnetic beads (Miltenyi Biotec). We injected 10⁷ CFSE-labeled B6 CD45.1⁺ or sorted B6 CD45.1⁺ CD44^{low} T cells for flow cytometric studies and 10⁷ CellTracker Red CMTPX-labeled CBA or B6 T cells for imaging studies.

ELISPOT

CD8⁺ T cells (2×10^5), purified from spleens of untransplanted B6 *aly/aly* mice or from lung allografts 7 days after B6C3F2 K^{k/b} *aly/aly* \rightarrow splenectomized B6 *aly/aly* transplantation were cultured with irradiated stimulators (6×10^5) (syngeneic H-2K^b, allogeneic H-2K^k, or third party H-2K^d) at a 1:3 ratio in plates coated with capture mouse IFN- γ -specific mAb (BD Biosciences). After 24 h, cells were incubated with biotinylated IFN- γ -specific Ab.

³Abbreviations used in this paper: EYFP, enhanced yellow fluorescent protein; BALT, bronchus-associated lymphoid tissue; FDC, follicular dendritic cell; PNA_d, peripheral node addressin.

Flow cytometry

Cells were stained with fluorochrome-labeled anti-CD45.1, anti-CD45.2, anti-CD4, anti-CD8, and anti-CD69 Abs and their isotype controls (12).

Two-photon microscopy

Tissue was imaged with a custom-built, video-rate two-photon microscope. Fluorescence emission was detected as red, green and blue signal channels. Each plane consisted of an image of $200 \times 225 \mu\text{m}$. The z -stacks were acquired by taking 31 sequential steps at $2.5\text{-}\mu\text{m}$ spacing. We averaged 15 video frames for each z -slice. Tissue volumes ($75 \times 200 \times 225 \mu\text{m}$) containing 11–13 cells were analyzed (13). Neighboring distributions (cells within a centroid to centroid distance $<25 \mu\text{m}$ in three-dimensional space) were compared with a Monte Carlo simulation of randomly distributed cells of equal density.

Immunostaining

Immunostaining was performed as previously described (14). Primary Abs used were anti-peripheral node addressin (PNAd; MECA-79) and anti-CD21 (7G6) (BD Biosciences).

Statistical analysis

Neighboring distribution of T cells was tested by Mann-Whitney U test, and CD69 expression and ELISPOT assays were analyzed with Student's t test.

Results and Discussion

In humans, acute rejection of lungs precedes that of hearts after heart-lung transplantation (15). We noticed that C3H lungs already have histological evidence of acute rejection 3 days after transplantation into B6 hosts (Fig. 1A). To determine where T cells are activated following lung transplantation, we injected CFSE-labeled CD45.1⁺ T cells into B6 recipients of C3H lungs at the time of engraftment. Three days later we observed marked proliferation of CD4⁺ and CD8⁺ T cells in the transplanted lung, but not in the draining lymph nodes or the spleen (Fig. 1B). Memory T cells, generated through in vivo immunization with alloantigen, can mediate cardiac allograft rejection in the absence of secondary lymphoid organs (16). To evaluate whether naive T cells can be activated in lung allografts, we injected CD44^{low}CD45.1⁺ T cells into B6 recipients of C3H lungs. We observed proliferation of these naive T cells in lung allografts, but not in the draining lymph nodes 3 days after transfer (Fig. 1C). Thus, priming of alloreactive T cells in lungs is not dependent on preexisting memory T cells. The absence of proliferation in draining lymph nodes and spleen could be explained by a temporal requirement for alloantigen presentation in secondary lymphoid organs. To evaluate the site of T cell activation at later time points, we injected CFSE-labeled CD45.1⁺ T cells 4 days after transplantation and analyzed their proliferation 3 days later. Again, there was marked proliferation of CD4⁺ and CD8⁺ T cells in the lung allografts (Fig. 1D). In addition, there was significant proliferation of CD4⁺ and CD8⁺ T cells in the draining lymph nodes. By 7 days after transplantation, C3H → B6 lung allografts have evidence of severe acute rejection (Fig. 1E). Syngeneic B6 lungs are free of inflammation 7 days after transplantation and T cells do not proliferate after injection into the recipients of syngeneic lungs (Fig. 1, F and G).

Graft-resident, donor-derived dendritic cells have been shown to migrate to the recipient's secondary lymphoid organs after transplantation, where they are widely thought to initiate alloimmune responses. Specifically, within a few days after vascularized heart transplantation, donor-derived dendritic cells colocalize with CD4⁺ T cells in the recipient's spleen (17). We next wanted to determine where T cells are localized in lung grafts at early time points after transplantation. For this purpose, we transplanted B6 lungs that express

EYFP under the endogenous CD11c promoter (CD11c-EYFP⁺) into CBA hosts and evaluated the recipients with two-photon microscopy 30 h later. We have previously reported that transplantation of B6 lungs into CBA hosts results in allograft rejection comparable to that observed in the C3H → B6 strain combination (12). We observed clustering of T cells in allogeneic lungs (Fig. 2A). Notably, many T cells in lung allografts clustered around donor-derived CD11c⁺ cells with a dendritic morphology. The clustering of adoptively transferred T cells has been described as a sensitive readout for T cell activation and has also coincided with CD69 expression on adoptively transferred, graft-infiltrating T cells at this time point (13). To quantitatively assess T cell clustering, we compared the neighboring distribution of adoptively transferred, recipient-matched T cells in allogeneic grafts to a random T cell distribution. The allogeneic T cell neighboring distribution was significantly different from a simulated random neighboring distribution, and graft-infiltrating T cells had up to seven neighbors within 25 μm. Only rare donor-derived CD11c⁺ cells were present in draining lymph nodes of allogeneic lung recipients at this time point, and T cells were randomly distributed (Fig. 2B). At 4 days after transplantation we observed an increased number of donor-derived CD11c⁺ cells in the lymph nodes. When we injected T cells 4 days after engraftment and evaluated those 30 h later, we found that T cells clustered around CD11c⁺ cells in both lung graft and draining lymph nodes (Fig. 2, C and D). The neighboring distribution in syngeneic lungs did not differ significantly from a random T cell distribution (Fig. 2E). Thus, these observations indicate that in addition to activation in secondary lymphoid organs, T cells can be primed in the lung graft itself after transplantation. T cell activation in the graft may be responsible for the initiation of lung rejection.

The *aly/aly* mice are a highly stringent model for evaluating the role of secondary lymphoid organs in promoting immune responses in transplant models (18) (3). Importantly, naive *aly/aly* T cells are able to mount productive alloimmune responses and trigger allograft rejection (3). We confirmed previous observations that although wild-type B6 mice reject C3H hearts acutely, C3H hearts transplanted into splenectomized B6 *aly/aly* hosts survive long term, indicating that secondary lymphoid organs are necessary for cardiac allograft rejection (3). Although C3H hearts transplanted into wild-type B6 recipients have histological evidence of acute rejection at day 7, they remain free of inflammation at both 7 and 100 days after transplantation into splenectomized B6 *aly/aly* hosts (data not shown). However, C3H lungs show severe acute rejection 7 days after transplantation into splenectomized B6 *aly/aly* hosts (Fig. 3A). To exclude the possibility that the rejection of C3H lungs was dependent on lymph nodes within the donor lung, we used B6C3F2 K^{k/b} *aly/aly* mice as donors (5, 19). Seven days after transplantation into splenectomized B6 *aly/aly* hosts, B6C3F2 K^{k/b} *aly/aly* lungs had severe rejection (Fig. 3B). The frequency of CD8⁺ T cells isolated from acutely rejecting grafts producing IFN-γ in response to donor alloantigen was significantly higher than that of CD8⁺ T cells from untransplanted B6 *aly/aly* mice (Fig. 3C). Although, consistent with previous reports, graft-infiltrating CD8⁺ T cells were reactive to both donor and third party stimulators, significantly more CD8⁺ T cells produced IFN-γ after stimulation with the donor than third party Ags (20). We next injected CFSE-labeled CD45.1⁺ T cells into splenectomized B6 *aly/aly* recipients of B6C3F2 K^{k/b} *aly/aly* lungs at the time of engraftment. At 30 h after adoptive transfer CD69 was expressed on a portion of T cells within the lung graft and to a markedly lower extent within the contralateral lung or bone marrow, a site where T cells can be activated in the absence of secondary lymphoid organs (Fig. 3D) (21). We did not observe division of T cells at 30 h following adoptive transfer. After 3 days, T cells within lung grafts, but not contralateral lungs or bone marrow, had undergone marked proliferation, comparable to that seen after C3H → B6 transplantation (Fig. 3E). Similarly, we observed proliferation of adoptively transferred CD44^{low} naive T cells within lung grafts (supplemental Fig. 1).⁴ With or without adoptive transfer B6C3F2 K^{k/b} *aly/aly* lungs had evidence of acute rejection 3 days after

transplantation into splenectomized B6 *aly/aly* recipients (Fig. 3F). Similar to native *aly/aly* lungs, syngeneic B6 *aly/aly* lungs harvested 7 days after transplantation have virtually no inflammation, and T cells did not proliferate after injection into splenectomized B6 *aly/aly* recipients of B6 *aly/aly* lungs (Fig. 3, G and H). Thus, we show for the first time that secondary lymphoid organs are not necessary for the activation of alloreactive T cells and acute rejection following lung transplantation.

Our findings may explain previous clinical observations documenting a very rapid onset of acute lung rejection (15). Based on morphological studies in the rat model, it was thought that rapid initiation of lung rejection could be attributed to a local proliferative response facilitated by the mucosal immune system such as bronchus-associated lymphoid tissue (BALT) (22). Importantly, unlike rats in which BALT is constitutively expressed, BALT is absent in the lungs of healthy humans and mice (23). Rejected mouse grafts in both wild-type and *aly/aly* mice lacked features characteristic of BALT such as follicular dendritic cells (FDC) or expression of peripheral lymph node addressin, indicating that organized BALT is not required to initiate alloimmune responses to lungs (Fig. 3I and supplemental Fig. 2).

Direct allorecognition, the pathway responsible for the initiation of allograft rejection, is thought to depend on the migration of donor-derived APCs to secondary lymphoid organs, where they encounter and activate alloreactive T cells (17). Although our results suggest that this pathway is also operative after lung transplantation, as we observe T cell clustering and proliferation in draining lymph nodes at later time points, the activation of T cells within the lung itself suffices to initiate acute rejection. We show that recipient T cells cluster predominantly around lung-resident, donor-derived CD11c⁺ cells at early time points after transplantation. To our knowledge, this is the first observation that T cells can be primed by interactions with dendritic cells outside of secondary lymphoid organs following transplantation. Future studies need to address which signals within lungs are essential for the initiation of alloimmune responses.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

1. Medawar PB. The homograft reaction. Proc R Soc London. 1958; 149:145–166. [PubMed: 13614379]
2. Barker CF, Billingham RE. The role of afferent lymphatics in the rejection of skin homografts. J Exp Med. 1968; 128:197–221. [PubMed: 4873840]
3. Lakkis FG, Arakelov A, Konieczny BT, Inoue Y. Immunologic ‘ignorance’ of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med. 2000; 6:686–688. [PubMed: 10835686]
4. Zhou P, Hwang KW, Palucki D, Kim O, Newell KA, Fu YX, Alegre ML. Secondary lymphoid organs are important but not absolutely required for allograft responses. Am J Transplant. 2003; 3:259–266. [PubMed: 12614279]
5. Wang J, Dong Y, Sun JZ, Taylor RT, Guo C, Alegre ML, Williams IR, Newell KA. Donor lymphoid organs are a major site of alloreactive T-cell priming following intestinal transplantation. Am J Transplant. 2006; 6:2563–2571. [PubMed: 16952298]

⁴The online version of this article contains supplemental material.

6. Beilhack A, Schulz S, Baker J, Beilhack GF, Nishimura R, Baker EM, Landan G, Herman EI, Butcher EC, Contag CH, Negrin RS. Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. *Blood*. 2007; 111:2919–2928. [PubMed: 17989315]
7. Lawrence CW, Braciale TJ. Activation, differentiation, and migration of naive virus-specific CD8⁺ T cells during pulmonary influenza virus infection. *J Immunol*. 2004; 173:1209–1218. [PubMed: 15240712]
8. Yoon H, Legge KL, Sung SS, Braciale TJ. Sequential activation of CD8⁺ T cells in the draining lymph nodes in response to pulmonary virus infection. *J Immunol*. 2007; 179:391–399. [PubMed: 17579060]
9. Ingulli E, Funatake C, Jacovetty EL, Zanetti M. Cutting edge: antigen presentation to CD8 T cells after influenza A virus infection. *J Immunol*. 2009; 182:29–33. [PubMed: 19109130]
10. Constant SL, Brogdon JL, Piggott DA, Herrick CA, Visintin I, Ruddle NH, Bottomly K. Resident lung antigen-presenting cells have the capacity to promote Th2 T cell differentiation in situ. *J Clin Invest*. 2002; 110:1441–1448. [PubMed: 12438442]
11. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, Hartson L, Sprague F, Goodrich S, Woodland DL, Lund FE, Randall TD. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. *Nat Med*. 2004; 10:927–934. [PubMed: 15311275]
12. Okazaki M, Krupnick AS, Kornfeld CG, Lai JM, Ritter JH, Richardson SB, Huang HJ, Das NA, Patterson GA, Gelman AE, Kreisel D. A mouse model of orthotopic vascularized aerated lung transplantation. *Am J Transplant*. 2007; 7:1672–1679. [PubMed: 17511692]
13. Zinselmeyer BH, Dempster J, Gurney AM, Wokosin D, Miller M, Ho H, Millington OR, Smith KM, Rush CM, Parker I, et al. In situ characterization of CD4⁺T cell behavior in mucosal and systemic lymphoid tissues during the induction of oral priming and tolerance. *J Exp Med*. 2005; 201:1815–1823. [PubMed: 15928201]
14. Okazaki M, Gelman AE, Tietjens JR, Ibricevic A, Kornfeld CG, Huang HJ, Richardson SB, Lai J, Garbow JR, Patterson GA, et al. Maintenance of airway epithelium in acutely rejected orthotopic vascularized mouse lung transplants. *Am J Respir Cell Mol Biol*. 2007; 37:625– 630. [PubMed: 17717320]
15. McGregor CG, Baldwin JC, Jamieson SW, Billingham ME, Yousem SA, Burke CM, Oyer PE, Stinson EB, Shumway NE. Isolated pulmonary rejection after combined heart-lung transplantation. *J Thorac Cardiovasc Surg*. 1985; 90:623– 626. [PubMed: 3930886]
16. Chalasani G, Dai Z, Konieczny BT, Baddoura FK, Lakkis FG. Recall and propagation of allospecific memory T cells independent of secondary lymphoid organs. *Proc Natl Acad Sci USA*. 2002; 99:6175–6180. [PubMed: 11983909]
17. Larsen CP, Morris PJ, Austyn JM. Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. *J Exp Med*. 1990; 171:307–314. [PubMed: 2404081]
18. Tesar BM, Chalasani G, Smith-Diggs L, Baddoura FK, Lakkis FG, Goldstein DR. Direct antigen presentation by a xenograft induces immunity independently of secondary lymphoid organs. *J Immunol*. 2004; 173:4377– 4386. [PubMed: 15383567]
19. Nasr IW, Reel M, Oberbarnscheidt MH, Mounzer RH, Baddoura FK, Ruddle NH, Lakkis FG. Tertiary lymphoid tissues generate effector and memory T cells that lead to allograft rejection. *Am J Transplant*. 2007; 7:1071–1079. [PubMed: 17359505]
20. Hricik DE, Rodriguez V, Riley J, Bryan K, Tary-Lehmann M, Greenspan N, DeJelo C, Schulak JA, Heeger PS. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon- γ independently predicts renal function in kidney transplant recipients. *Am J Transplant*. 2003; 3:878– 884. [PubMed: 12814480]
21. Feuerer M, Beckhove P, Garbi N, Mahnke Y, Limmer A, Hommel M, Hammerling GJ, Kyewski B, Hamann A, Umansky V, Schirmmacher V. Bone marrow as a priming site for T-cell responses to blood-borne antigen. *Nat Med*. 2003; 9:1151–1157. [PubMed: 12910264]
22. Prop J, Wildevuur CR, Nieuwenhuis P. Lung allograft rejection in the rat. II. Specific immunological properties of lung grafts. *Transplantation*. 1985; 40:126–131. [PubMed: 3895615]

23. Pabst R, Gehrke I. Is the bronchus-associated lymphoid tissue (BALT) an integral structure of the lung in normal mammals, including humans? *Am J Respir Cell Mol Biol.* 1990; 3:131–135. [PubMed: 2378747]




FIGURE 1. Lung transplantation in wild-type mice. *A*, C3H → B6 lung grafts on postoperative day 3. *B*, Division of adoptively transferred CFSE-labeled CD45.1⁺ T cells in lung grafts, contralateral lungs (C. Lung), draining lymph nodes (LN) and spleen 3 days after C3H → B6 lung transplantation. *C*, Division of adoptively transferred, CFSE-labeled CD44^{low}CD45.1⁺ T cells 3 days after C3H → B6 lung transplantation. *D*, Division of T cells injected on postoperative day 4 and analyzed 3 days later after C3H → B6 lung transplantation. *E* and *F*, C3H → B6 (*E*) and B6 → B6 (*F*) lung grafts on postoperative day 7. *G*, Division of T cells injected on day 0 and analyzed in lung grafts on postoperative day 3 after B6 → B6 transplantation. Data are representative of at least three independent experiments.





FIGURE 2.

T cell clustering in lung grafts and draining lymph nodes. *A*, B6 CD11c-EYFP⁺ → CBA graft showing adoptively transferred CBA T cells (red), CD11c-EYFP⁺ cells (green), and collagen fibers (blue). T cell neighboring analysis was performed on 14 representative *z*-stacks from three independent experiments (filled bars) and was significantly different from that performed on randomly placed T cells of equal density (hatched bars) ($p < 0.05$). Dot plot shows CD69 expression ($11.5 \pm 1\%$; $n = 3$) on adoptively transferred, CFSE-labeled, graft-infiltrating congenic T cells in C3H → B6 transplants at the same time point ($p < 0.05$, compared with T cells isolated from native untransplanted lungs ($3.5\% \pm 1.4$; $n = 3$)). *B*, Adoptively transferred CBA T cells in draining lymph node 30 h after B6 CD11c-EYFP⁺ → CBA transplantation. *C* and *D*, CBA T cells injected on postoperative day 4 after B6 CD11c-EYFP⁺ → CBA transplantation and analyzed in lung grafts (*C*) and draining lymph nodes (*D*) 30 h after injection. *E*, B6 T cells, injected into B6 CD11c-EYFP⁺ → B6 transplants on day 0 and analyzed in lung grafts 30 h later. T cell neighboring distributions in *C* and *D* ($p < 0.05$), but not in *B* and *E* ($p < 0.1$), were significantly different from those of randomly placed T cells. Space bar, 20 μm .

**FIGURE 3.**

Lung transplantation in the absence of secondary lymphoid organs. *A*, C3H \rightarrow splenectomized B6 *aly/aly* lung grafts on postoperative day 7. *B*, B6C3F2 K^{k/b} *aly/aly* \rightarrow splenectomized B6 *aly/aly* lung grafts on postoperative day 7. *C*, Frequencies of CD8⁺ T cells isolated from spleens of untrans-planted B6 *aly/aly* mice ($n = 3$) or from B6C3F2 K^{k/b} *aly/aly* \rightarrow splenectomized B6 *aly/aly* lung transplants (postoperative day 7) ($n = 5$) producing IFN- γ after culture with donor-type (K^k), recipient-type (K^b), or third party (K^d) stimulators. *D* and *E*, CD69 expression on T cells in lung grafts ($11.2 \pm 0.7\%$) vs contralateral lungs (C. Lung; $2.5 \pm 0.6\%$, $p < 0.05$) and bone marrow (B. marrow; $2.8 \pm 0.9\%$, $p < 0.05$) at 30 h ($n = 4$) and T cell division 3 days after injection into B6C3F2 K^{k/b} *aly/aly* \rightarrow splenectomized B6 *aly/aly* transplants. *F*, B6C3F2 K^{k/b} *aly/aly* \rightarrow splenectomized B6 *aly/aly* lungs on postoperative day 3. *G*, B6 *aly/aly* \rightarrow splenectomized B6 *aly/aly* lungs on postoperative day 7. *H*, Proliferation of adoptively transferred T cells in lung grafts 3 days after B6 *aly/aly* \rightarrow splenectomized B6 *aly/aly* transplantation. Data are representative of at least three independent experiments. *I*, Immunostaining for PNAd (*top*; original magnification $\times 200$) and FDC (*bottom*; original magnification $\times 400$) on C3H \rightarrow B6 and B6C3F2 K^{k/b} *aly/aly* \rightarrow splenectomized B6 *aly/aly* lung grafts on postoperative day 7. Positive and isotype control Ab staining shown on axillary lymph node (PNAd) and spleen (FDC) from wild-type (WT) B6 mouse.